NWBO Northwest Biotherapeutics, Inc.

-

Northwest Biotherapeutics Reported Earnings

Friday, August 14, 2026 · 12:00 AM ET

Northwest Biotherapeutics (NWBO) reported a loss of $0.01 per share on revenue of $0.81 million for the . . Revenue grew 516.03% on a year-over-year basis.

Northwest Biotherapeutics Inc is a development stage biotechnology company engaged in the development of immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.01)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth0.0 %
Reported Revenue
$0.81M
Revenue Estimate
Revenue Surprise
Revenue Growth516.0 %